REVIEW

4182 Impact of mobile health and medical applications on clinical practice in gastroenterology
Kernebeck S, Busse TS, Böttcher MD, Weitz J, Ehlers J, Bork U

4198 Endoscopic management of gastrointestinal leaks and fistulae: What option do we have?
Cereatti F, Grassia R, Drago A, Conti CB, Donatelli G

4218 Watch and wait approach in rectal cancer: Current controversies and future directions

4240 Role of long noncoding RNA-mediated competing endogenous RNA regulatory network in hepatocellular carcinoma
Niu ZS, Wang WH, Dong XN, Tian LML

MINIREVIEWS

4261 Gadoxetic acid magnetic-enhanced resonance imaging in the diagnosis of cholangiocarcinoma

ORIGINAL ARTICLE

Basic Study

4272 Rno_circ_0005139 regulates apoptosis by targeting Wnt5a in rat anorectal malformations
Liu D, Qu Y, Cao ZN, Jia HM

Clinical and Translational Research

4288 Role of nutritional status and nutritional support in outcome of hepatitis B virus-associated acute-on-chronic liver failure
Chang Y, Liu QY, Zhang Q, Rong YM, Lu CZ, Li H

Retrospective Cohort Study

4302 Evaluation of intrahepatic manifestation and distant extrahepatic disease in alveolar echinococcosis
Graeter T, Bao HH, Shi R, Liu WY, Li WX, Jiang Y, Schmidberger J, Brumpt E, Delabrousse E, Kratzer W, the XUUB Consortium

Retrospective Study

4316 Multivariate predictive model for asymptomatic spontaneous bacterial peritonitis in patients with liver cirrhosis
Tu B, Zhang YN, Bi JF, Xu Z, Zhao P, Shi L, Zhang X, Yang G, Qin EQ
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>4343</td>
<td>Patients' perspectives on smoking and inflammatory bowel disease: An online survey in collaboration with European Federation of Crohn's and Ulcerative Colitis Associations</td>
<td>Le Berre C, Loy L, Lönnfors S, Avedano L, Piomani D</td>
</tr>
<tr>
<td>4356</td>
<td>Dysregulation of microRNA in cholangiocarcinoma identified through a meta-analysis of microRNA profiling</td>
<td>Likhitrattanapisal S, Kumkate S, Ajawatanawong P, Wongprasert K, Tohtong R, Janvilisri T</td>
</tr>
<tr>
<td>4372</td>
<td>Multifocal gastrointestinal epithelioid angiosarcomas diagnosed by endoscopic mucosal resection: A case report</td>
<td>Chen YW, Dong J, Chen WY, Dai YN</td>
</tr>
</tbody>
</table>
ABOUT COVER

Editorial board member of *World Journal of Gastroenterology*, Dr. Feng Yang is a distinguished Associate Professor at the Shanghai Medical College Affiliated to Fudan University in Shanghai, China. Having received his Bachelor's degree from Fudan University in 2003, Dr. Yang undertook his postgraduate study and surgical resident training at the Department of Surgery in Huashan Hospital Affiliated to Fudan University, receiving his PhD in 2008. He became Associate Chief Physician at the Division of Pancreatic Surgery in Huashan Hospital Affiliated to Fudan University in 2015 and has held the position since. His ongoing research interests involve basic and clinical study of metastasis and recurrence of pancreatic neoplasms, including pancreatic carcinomas, neuroendocrine tumors and solid pseudopapillary tumors. Currently, he serves as a Young Member of the Pancreatic Cancer Committee, Chinese Anti-cancer Association. He also serves as a peer reviewer for many international academic journals.

AIMS AND SCOPE

The primary aim of *World Journal of Gastroenterology* (*WJG, World J Gastroenterol*) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. *WJG* mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING

The *WJG* is now indexed in Current Contents®/Clinical Medicine, Science Citation Index Expanded (also known as Sciname®/Journal Citation Reports®, Index Medicus, MEDLINE, PubMed, PubMed Central, and Scopus. The 2020 edition of Journal Citation Report® cites the 2019 impact factor (IF) for *WJG* as 3.665; IF without journal self cites: 3.534; 5-year IF: 4.048; Ranking: 35 among 88 journals in gastroenterology and hepatology; and Quartile category: Q2.

RESPONSIBLE EDITORS FOR THIS ISSUE

Electronic Editor: Yu-Jie Ma, Production Department Director: Xiang Li; Editorial Office Director: Ze-Mao Gong.

NAME OF JOURNAL

*World Journal of Gastroenterology*

ISSN

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

LAUNCH DATE

October 1, 1995

FREQUENCY

Weekly

EDITORS-IN-CHIEF

Andrzej S Tarnawski, Subrata Ghosh

EDITORIAL BOARD MEMBERS

http://www.wjgnet.com/1007-9327/editorialboard.htm

PUBLICATION DATE

August 7, 2020

COPYRIGHT

© 2020 Baishideng Publishing Group Inc
Role of long noncoding RNA-mediated competing endogenous RNA regulatory network in hepatocellular carcinoma

Zhao-Shan Niu, Wen-Hong Wang, Xian-Ning Dong, Li-Mei-Li Tian

Abstract

Long noncoding RNAs (lncRNAs) and microRNAs (miRNAs) are noncoding RNAs (ncRNAs) that occupy over 90% of the human genome, and their main function is to directly or indirectly regulate messenger RNA (mRNA) expression and participate in the tumorigenesis and progression of malignances. In particular, some lncRNAs can interact with miRNAs as competing endogenous RNAs (ceRNAs) to modulate mRNA expression. Accordingly, these RNA molecules are interrelated and coordinate to form a dynamic lncRNA-mediated ceRNA regulatory network. Mounting evidence has revealed that lncRNAs that act as ceRNAs are closely related to tumorigenesis. To date, numerous studies have established many different regulatory networks in hepatocellular carcinoma (HCC), and perturbations in these ceRNA interactions may result in the initiation and progression of HCC. Herein, we emphasize recent advances concerning the biological function of lncRNAs as ceRNAs in HCC, with the aim of elucidating the molecular mechanism underlying these HCC-related RNA molecules and providing novel insights into the diagnosis and treatment of HCC.

Key words: Hepatocellular carcinoma; Long noncoding RNA; MicroRNA; Competing endogenous RNA; Function; Mechanism
INTRODUCTION

Hepatocellular carcinoma (HCC) is a malignant tumor with high morbidity and mortality worldwide[1]. However, the pathogenesis of HCC remains elusive. Although great progress has been made in the diagnosis and treatment of HCC in recent years, the overall and long-term effects of treatment in patients with advanced HCC are poor. Therefore, in-depth studies are needed to explore the mechanisms underlying HCC occurrence and development, which will contribute to the development of effective diagnostic biomarkers and therapeutic targets for HCC.

Protein-coding genes account for less than 2% of the human genome, while most of the genome is composed of genes that are transcribed into noncoding RNAs (ncRNAs)[2]. ncRNAs are divided into long noncoding RNAs (lncRNAs), small ncRNAs, and intermediate-sized ncRNAs by length[3]. lncRNAs have been identified as key regulators of transcription and translation and are involved in a variety of biological processes by regulating gene expression[4]. MicroRNAs (miRNAs) are small ncRNAs that interact with the 3'-untranslated region (3'-UTR) of target mRNAs to facilitate their degradation or inhibit their translation. MiRNAs play a critical role in tumorigenesis and tumor cell proliferation, migration, and invasion[5]. lncRNAs and miRNAs are regulatory ncRNAs, and dysregulation of lncRNAs or miRNAs is involved in tumor initiation and progression either via the activation or inhibition of target genes[6].

Existing evidence indicates that there are interactions among RNA molecules, such as lncRNAs and miRNAs[7], miRNAs and mRNAs[8], and lncRNAs and mRNAs[9]; these RNA molecules are interrelated and collaborate to form a dynamic regulatory network of lncRNAs acting as competitive endogenous RNAs (ceRNAs)[10]. The ceRNA mechanism is one of the important ways by which an lncRNA exerts its posttranscriptional gene regulation in the cytoplasm, and perturbations in these ceRNA interactions contribute to tumor initiation and progression. Currently, the identified ceRNAs include protein-coding RNAs (mRNAs) and ncRNAs, such as lncRNAs, pseudogene transcripts, viral RNAs, and circular RNAs (circRNAs). lncRNAs are the main component of the ceRNA network, as they regulate mRNA expression by acting as miRNA sponges. To date, numerous different regulatory networks of lncRNAs acting as ceRNAs in HCC have been established. Accumulating evidence has revealed that lncRNAs acting as ceRNAs play pivotal roles in HCC initiation and progression[11,12]. Herein, we emphasize recent advances concerning the biological function of lncRNAs as ceRNAs in HCC, with the aim of elucidating the molecular mechanism underlying these HCC-related RNA molecules and providing novel insights into the diagnosis and treatment of HCC.

MECHANISM OF ACTION OF LNCRNAS INVOLVED IN THE CERNA REGULATORY NETWORK

Theoretically, any RNA molecule with a miRNA binding site can bind to a miRNA to form an intricate ceRNA regulatory network. RNA transcripts in the ceRNA network...
are in a state of equilibrium under physiological conditions; once perturbed, this will lead to the occurrence of disease[11,12]. In the ceRNA regulatory network, miRNA acts as a bridge between ncRNA and mRNA and negatively regulates the expression of its target mRNA[13]. There is growing evidence that each miRNA can regulate many transcripts. In turn, RNA transcripts with different miRNA response elements (MREs) may also be targets of multiple miRNAs[14]. The multiplicity of targets allows RNA and RNA to interact with each other by competitively binding to a common MRE, and the same MRE is the structural basis for the binding of different RNAs[15].

In addition to directly regulating mRNAs, IncRNAs can also indirectly affect the expression of target genes by sponging miRNAs[16]. Structurally, most IncRNAs are similar to miRNAs, which makes their patterns of gene regulation more diverse and extensive and unaffected by translation[17]. This may be the reason why many IncRNAs can act as ceRNAs to sponge miRNAs to inhibit miRNAs from degrading their target mRNAs. In general, the more miRNA binding sites there are on an IncRNA, the stronger the competition[18]. When IncRNAs are expressed at low levels, they can bind only a few miRNAs, and the remaining miRNAs interact with mRNAs to promote their degradation. In contrast, when IncRNAs are expressed at high levels, they can combine with more miRNAs, thus relieving the inhibitory effect of miRNAs on their target mRNAs. The new regulatory pattern of IncRNA-miRNA-mRNA is an extension of the traditional miRNA-mRNA regulatory model[19].

ROLE OF LNCRNAS AS CERNAS IN HCC

To date, mounting evidence indicates that oncogenic or tumor suppressive IncRNAs can regulate their target genes by acting as ceRNAs to sponge miRNAs[20,21], thereby affecting glucose metabolism, immune escape, autophagy, angiogenesis, liver cancer stem cells (LCSCs), proliferation, apoptosis, epithelial-mesenchymal transition (EMT), migration, invasion, metastasis, chemoresistance, and radioresistance in HCC (Figure 1). Specifically, the majority of the identified IncRNAs exhibit oncogenic properties that function as ceRNAs for tumor suppressive miRNAs, thereby activating the expression of oncogenic mRNAs to promote HCC occurrence and progression (Figure 2A). In addition, some IncRNAs exhibit tumor suppressive properties, acting as ceRNAs for oncogenic miRNAs (oncomiRs), thus upregulating the expression of tumor suppressive targets to inhibit HCC occurrence and progression (Figure 2B). Here, we elucidate the functions of some IncRNA-mediated ceRNA regulatory networks in HCC (Table 1). Note that there are many abbreviations in this paper, so they are listed and expanded in Table 1 below.

Glucose metabolism

The “reprogramming” of glucose metabolism is regarded as a prominent characteristic of cancer cells. A large amount of lactic acid produced by glycolysis forms an inflammatory microenvironment around the tumor, which contributes to tumor cell proliferation, EMT, invasion, metastasis,chemoresistance, and resistance to chemotherapy and radiotherapy. Existing evidence indicates that aberrant glucose metabolism plays a pivotal role in the invasion and metastasis of HCC[22,23]. The mechanism of abnormal activation of glycolysis in cancer cells is complex, and many studies have confirmed that IncRNAs play a significant role in modulating glycolysis by sponging miRNAs in HCC, among which oncogenic IncRNAs that act as ceRNAs can promote glycolysis. For instance, lactate dehydrogenase isoform A (LDHA), a glycolytic enzyme, can mediate aerobic glycolysis in cancer cells[24]. The IncRNA RAET1K, as a miR-100-5p sponge, can enhance LDHA expression and facilitate hypoxia-induced glycolysis, thereby promoting HCC progression[25]. In addition, hemikinase 2 (HK2) is another glycolytic enzyme related to glycolysis in cancer cells[26], and the IncRNA TUG1 induces glycolysis and promotes HCC metastasis by acting as a ceRNA to enhance HK2 expression by sponging miR-455-3p[27]. Additionally, hypoxia-inducible factor (HIF) 1 has been confirmed to promote aerobic glycolysis in cancer[28], and the IncRNA HOTAIR promotes glycolysis by acting as a ceRNA for miR-130a-3p to increase HIF1 expression in HCC cells[29]. By contrast, tumor suppressive IncRNAs that act as ceRNAs can inhibit glycolysis in HCC. For example, endoplasmic reticulum protein 29 (ERp29), an endoplasmic reticulum protein, and the IncRNA MEG3 are downregulated in high-glucose (HG) HCC cells, while miR-483-3p is upregulated in HG HCC cells. Mechanistically, the overexpression of MEG3 inhibits glycolysis by sponging miR-483-3p to increase ERp29 expression in HCC[30]. Currently, antitumor drugs that target glucose metabolism are being researched and developed;
## Table 1 Long noncoding RNA-mediated competitive endogenous RNA network in hepatocellular carcinoma

<table>
<thead>
<tr>
<th>LncRNA</th>
<th>Dysregulation</th>
<th>Sponged miRNA(s)</th>
<th>Affected mRNA(s)/signaling pathway(s)</th>
<th>Biological functions</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>RAET1K</td>
<td>Up-regulated</td>
<td>miR-100-5p</td>
<td>LDHA</td>
<td>Enhances HCC glycolysis and progression</td>
<td>Zhou et al[24]</td>
</tr>
<tr>
<td>TUG1</td>
<td>Up-regulated</td>
<td>miR-455-3p</td>
<td>HK2</td>
<td>Promotes HCC glycolysis and metastasis</td>
<td>Lin et al[21]</td>
</tr>
<tr>
<td>HOTAIR</td>
<td>Up-regulated</td>
<td>miR-130a-3p, miR-218</td>
<td>HIF1, Bmi-1</td>
<td>Promotes glycolysis and HCC cell proliferation</td>
<td>Hu et al[23]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>miR-1</td>
<td>FOXC1</td>
<td>Promotes HCC cell proliferation, migration, and invasion</td>
<td>Su et al[27]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>miR-214-3p</td>
<td>FLOT1</td>
<td>Promotes HCC cell proliferation, migration, and invasion</td>
<td>Liu et al[27]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>miR-23b-3p</td>
<td>ZEB1</td>
<td>Promotes HCC invasion and metastasis</td>
<td>Yang et al[27]</td>
</tr>
<tr>
<td>MEG3</td>
<td>Down-regulated</td>
<td>miR-483-3p</td>
<td>ERp29</td>
<td>Inhibits glycolysis</td>
<td>Li et al[28]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>miR-9-5p</td>
<td>SOX11</td>
<td>Promotes HCC cell apoptosis and inhibits cell growth</td>
<td>Liu et al[28]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>miRNA-10a-5p</td>
<td>PTEN</td>
<td>Inhibits HCC cell proliferation, migration, and invasion</td>
<td>Zhang et al[29]</td>
</tr>
<tr>
<td>NEAT1</td>
<td>Up-regulated</td>
<td>miR-155</td>
<td>Tim-3</td>
<td>Facilitates CD8+ T cells-mediated immune escape</td>
<td>Yan et al[30]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>miR-335</td>
<td>c-Met-Akt pathway</td>
<td>Enhances HCC resistance to sorafenib</td>
<td>Chen et al[30]</td>
</tr>
<tr>
<td>FENDRR</td>
<td>Down-regulated</td>
<td>miR-423-5p</td>
<td>GADD45β</td>
<td>Suppresses Treg-mediated immune escape</td>
<td>Yu et al[31]</td>
</tr>
<tr>
<td>PVT1</td>
<td>Up-regulated</td>
<td>miR-365</td>
<td>ATG3</td>
<td>Promotes autophagy</td>
<td>Yang et al[31]</td>
</tr>
<tr>
<td>HNF1A-AS1</td>
<td>Up-regulated</td>
<td>hsa-miR-30b-5p</td>
<td>ATG5</td>
<td>Stimulates autophagy</td>
<td>Liu et al[32]</td>
</tr>
<tr>
<td>Ccat1</td>
<td>Up-regulated</td>
<td>miR-181a-5p, Let-7</td>
<td>ATG7, HMGA2 and c-Myc</td>
<td>Induces autophagy</td>
<td>Guo et al[32]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>miR-490-3p</td>
<td>CDK1</td>
<td>Promotes HCC cell proliferation and invasion</td>
<td>Dou et al[33]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>miR-30c-2-3p</td>
<td>CCNE1</td>
<td>Promotes HCC cell proliferation</td>
<td>Zhang et al[33]</td>
</tr>
<tr>
<td>HCG11</td>
<td>Up-regulated</td>
<td>miR-26a-5p</td>
<td>ATG12</td>
<td>Promotes autophagy</td>
<td>Li et al[34]</td>
</tr>
<tr>
<td>LINCO06665</td>
<td>Up-regulated</td>
<td>miR-186-5p</td>
<td>MAP4K3</td>
<td>Facilitates autophagy</td>
<td>Shan et al[34]</td>
</tr>
<tr>
<td>HULC</td>
<td>Up-regulated</td>
<td>miR-107</td>
<td>SPHK1</td>
<td>Promotes angiogenesis</td>
<td>Lu et al[35]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>miR-200a-3p</td>
<td>ZEB1</td>
<td>Enhances EMT and promotes HCC growth and metastasis</td>
<td>Li et al[35]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>miR-2052</td>
<td>MET</td>
<td>Promotes HCC cell proliferation, migration, and invasion</td>
<td>Zhang et al[36]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>miR-186</td>
<td>HMGA2</td>
<td>Promotes HCC growth and metastasis</td>
<td>Wang et al[36]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>miR-372-3p</td>
<td>Rab11a</td>
<td>Promotes HCC growth and metastasis</td>
<td>Cao et al[37]</td>
</tr>
<tr>
<td></td>
<td></td>
<td>miR-6825-5p, miR-</td>
<td>USP22</td>
<td>Increases HCC resistance</td>
<td>Xiong et al[38]</td>
</tr>
<tr>
<td>LncRNA</td>
<td>Regulation</td>
<td>miRNAs</td>
<td>Pathways/Effects</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>------------</td>
<td>--------</td>
<td>------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MALAT1</td>
<td>Up-regulated</td>
<td>miR-306-5p, miR-124-5p, miR-216b</td>
<td>FOXA1/CD24/Src pathway, PI3K/Akt pathway, HIF-2α pathway</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>miR-140</td>
<td>VEGF-A pathway, PI3K/Akt pathway, HIF-2α pathway</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>miR-124</td>
<td>PI3K/Akt pathway, HIF-2α pathway</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>miR-216b</td>
<td>Enhances HCC resistance to 5-FU</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>miR-144</td>
<td>PBX3</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>miR-122-5p</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>miR-122-5p</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>miR-144</td>
<td>PBX3</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>miR-122-5p</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GASS5</td>
<td>Down-regulated</td>
<td>miR-21, miR-135b, miR-1323</td>
<td>PDCD4 and PTEN, RECK, TP53INP1</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>miR-222</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>miR-222</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>miR-222</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>miR-222</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ASB16-AS1</td>
<td>Up-regulated</td>
<td>miR-1827</td>
<td>FZD4 Wnt/β-catenin pathway</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>miR-485-5p</td>
<td>FZD7 Wnt/β-catenin pathway</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>miR-5590-3p</td>
<td>SOX9 Wnt/β-catenin pathway</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>miR-26a-5p and miR-26b-5p</td>
<td>IL-6/STAT3 pathway and CDK8/LRF6 Wnt/β-catenin pathway</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>miR-10a-5p</td>
<td>NCoR2 Wnt/β-catenin pathway</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>miR-383</td>
<td>CCND1/PARP2 and PI3K/Akt pathway</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>miR-133a</td>
<td>IGF-IR PI3K/akt pathway</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>miR-106a-5p</td>
<td>PTEN PI3K/Akt pathway</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>miR-106a-5p</td>
<td>PTEN PI3K/Akt pathway</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>let-7c-5p</td>
<td>NAPI1 PI3K/akt pathway</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>miR-493-5p</td>
<td>OTUB1 PI3K-akt/FoxO3a pathway</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

References:
1. Zhang et al. [53]
2. Hou et al. [54]
3. He et al. [55]
4. Yuan et al. [56]
5. Mal et al. [57]
6. Yuan et al. [58]
7. Ji et al. [59]
8. Ma et al. [60]
9. Yuan et al. [61]
10. Yuan et al. [62]
11. Yuan et al. [63]
12. Yuan et al. [64]
13. Yuan et al. [65]
14. Yuan et al. [66]
15. Yuan et al. [67]
16. Yuan et al. [68]
17. Yuan et al. [69]
18. Yuan et al. [70]
19. Yuan et al. [71]
20. Yuan et al. [72]
<table>
<thead>
<tr>
<th>LncRNA</th>
<th>Regulation</th>
<th>miRNA</th>
<th>Target</th>
<th>Function</th>
</tr>
</thead>
<tbody>
<tr>
<td>SNHG12</td>
<td>Up-regulated</td>
<td>miR-199a/b-5p</td>
<td>MLK3</td>
<td>Promotes HCC cell proliferation and tumorigenicity</td>
</tr>
<tr>
<td>CASC2</td>
<td>Down-regulated</td>
<td>miR-362-5p</td>
<td>CYLD</td>
<td>Inhibits HCC cell migration and invasion</td>
</tr>
<tr>
<td>LINC-ROR</td>
<td>Up-regulated</td>
<td>miR-876-5p</td>
<td>FOXM1</td>
<td>Increases HCC resistance to sorafenib</td>
</tr>
<tr>
<td>LINC00169</td>
<td>Up-regulated</td>
<td>miR-132</td>
<td>PIK3R3</td>
<td>Promotes HCC resistance to sorafenib</td>
</tr>
<tr>
<td>FOXD2-AS1</td>
<td>Up-regulated</td>
<td>miR-340-5p</td>
<td>N/A</td>
<td>Enhances HCC resistance</td>
</tr>
<tr>
<td>SNHG3</td>
<td>Up-regulated</td>
<td>miR-128</td>
<td>CD151</td>
<td>Enhances HCC resistance</td>
</tr>
<tr>
<td>SNHG16</td>
<td>Up-regulated</td>
<td>miR-140-5p</td>
<td>N/A</td>
<td>Enhances HCC resistance to sorafenib</td>
</tr>
<tr>
<td>NRG2F1-AS1</td>
<td>Up-regulated</td>
<td>miR-363</td>
<td>ABCC1</td>
<td>Promotes HCC resistance to oxaliplatin</td>
</tr>
<tr>
<td>KCNQ1OT1</td>
<td>Up-regulated</td>
<td>miR-7-5p</td>
<td>ABCC1</td>
<td>Enhances HCC resistance to oxaliplatin</td>
</tr>
<tr>
<td>NRAL</td>
<td>Up-regulated</td>
<td>miR-340-5p</td>
<td>Nrf2</td>
<td>Facilitates HCC resistance to cisplatin</td>
</tr>
<tr>
<td>LINC01234</td>
<td>Up-regulated</td>
<td>miR-31-5p</td>
<td>MAGEA3</td>
<td>Promotes HCC resistance to cisplatin</td>
</tr>
<tr>
<td>CRNDE</td>
<td>Up-regulated</td>
<td>miR-33a</td>
<td>HMGA2</td>
<td>Promotes HCC resistance to 5-FU</td>
</tr>
<tr>
<td>KRAL</td>
<td>Down-regulated</td>
<td>miR-141</td>
<td>Keap1</td>
<td>Reverses HCC resistance to 5-FU</td>
</tr>
<tr>
<td>NEAT1_2</td>
<td>Up-regulated</td>
<td>miR-101-3p</td>
<td>WEE1</td>
<td>Enhances radio-resistance of HCC cells</td>
</tr>
<tr>
<td>LINC00473</td>
<td>Up-regulated</td>
<td>miR-345-5p</td>
<td>FOXP1</td>
<td>Promotes radio-resistance of HCC cells</td>
</tr>
</tbody>
</table>

HCC: Hepatocellular carcinoma; LncRNAs: Long noncoding RNAs; ceRNA: Competitive endogenous RNA; RAET1K: Retinoic acid early transcript 1K; LDHA: Lactate dehydrogenase isomerase A; TUG1: Taurine up-regulation gene 1; HK2: Hexokinase 2; HOTAIR: Homeobox transcript antisense RNA; HIF1: Hypoxia-inducible factor 1; Bmi-1:B lymphoma moloney murine leukemia virus insertion region 1; FOXC1: Forkhead box c1; FLOT1: Flotillin 1; ZEB1: Zinc finger E-box binding homeobox 1; MEG3: Maternally expressed gene 3; ERp29: ER protein 29; SOX11: SRY-related HMG-box protein 11; PTEN: Phosphatase and tensin homolog; NEAT1: Nuclear enriched abundant transcript 1; Tim-3: T cell immunoglobulin mucin-3; FENDR: Fetal-lethal noncoding developmental regulatory RNA; GADD45β: Growth arrest and DNA damage-inducible beta; PVT1: Plasmacytoma variant translocation 1; ATG3: Autophagy related genes 3; HNFA1-AS1: HNFA1 antisense RNA 1; ATG5: Autophagy related genes 5; CCAT1: Colon cancer associated transcript 1; ATG7: Autophagy related genes 7; HMGA2: High mobility group AT-hook 2; CDK1: Cyclin-dependent kinase 1; CCNE1: Cyclin E1; HCG11: HLA-DR-restricted antigen 11; ATG12: Autophagy related genes 12; LINC00665: Long intergenic non-protein coding RNA 665; MAP4K3: Mitogen-activated protein kinase 3; HULC: Highly upregulated in liver cancer; SPHK1: Sphingosine kinase 1; MET: Hepatocyte growth factor receptor; Rab11a: Member RAS oncogene family; USP22: Ubiquitin-specific peptidase 22; MALAT1: Metastasis-associated lung adenocarcinoma transcript 1; FOXC1: Forkhead box a1; VEGF: A: Vascular endothelial growth factor A; P3K/Akt pathway: Phosphoinositide-3-kinase/protein kinase B; CSC: Liver cancer stem cell; HIF-2α: Hypoxia-inducible factor 2α; TLN1: Talin 1; DANC: Differentiation antagonizing non-protein coding RNA; CTNNB1: Catenin beta-1; ANRIL: Antisense noncoding RNA in the INK4 locus; STAT3: Signal transducer and activator of transcription 3; N/A: Not available.; PBX3: Pre-B-cell leukemia homeobox 3; GA55: Growth arrest-specific 5; PDCD4: Programmed cell death 4; RECK: Cysteine-rich protein with Kazal motifs; TP53INP1: Tumor protein p53-induced nuclear protein 1; ASB16-AS1: ASB16 antisense RNA 1; Fzd4: Frizzled 4; DSCR8: Down syndrome critical region 8; ADAM10: A disintegrin and metalloproteinase 10; CCND1: Cyclin D1; PARP2: Poly ADP-ribose polymerase 2; DLEU1: Deleted in lymphocytic leukemia 1; IGF-1R: Insulin-like growth factor 1 receptor; TLE1: T cell leukemia/lymphoma 6; CDKN2B-AS1: CDKN2B antisense RNA 1; NAP1L1: Nucleosome assembly protein 1 like 1; mTOR: Mammalian rapamycin; GAS6-
the above findings suggest that the lncRNA-mediated ceRNA network could provide new ideas for inhibiting glycolysis in HCC.

**Immune escape**

Tumor immune escape refers to the phenomenon that tumor cells can survive and proliferate by escaping immune system-mediated recognition and attack by changing themselves or their tumor microenvironment\(^9\). Currently, the effectiveness of immunotherapy is limited by tumor immune escape. Thus, an in-depth exploration of the mechanisms of tumor immune escape may provide novel insights into tumor
immunotherapy. Current studies have shown that IncRNAs can modulate immune escape in HCC by acting as ceRNAs of miRNAs, among which oncogenic IncRNAs that function as ceRNAs can promote the immune escape of HCC cells. For example, NEAT1, a newly discovered oncogenic IncRNA, is specifically localized in nuclear paraspeckles and participates in paraspeckle formation and the transcriptional regulation of many genes. T cell immunoglobulin mucin-3 (Tim-3), an immune checkpoint molecule, can suppress the immune response, and the increased expression of Tim-3 within the tumor can inactivate killer T cells, thus preventing the death of tumor cells. Mechanistically, NEAT1 facilitates the CD8+ T cell-mediated immune escape of HCC cells by acting as a ceRNA for miR-155 to enhance Tim-3 expression. Conversely, tumor suppressive IncRNAs that act as ceRNAs can inhibit the immune escape of HCC cells. For instance, GADD45β, a tumor suppressor, is associated with antitumor immune responses, and CD4+ T cells lacking GADD45β are less responsive to the stimulation of T cell receptors or inflammatory cytokines. FENDRR, a tumor suppressor IncRNA, upregulates GADD45β by sponging miR-423-5p, thereby suppressing the immune escape of HCC cells. These findings suggest that the IncRNA-mediated ceRNA network is involved in mediating immune evasion in HCC and thus may be a promising therapeutic target for HCC immunotherapy.

**Autophagy**

Autophagy is closely associated with the development of malignant tumors and can promote tumor survival and proliferation by regulating interactions between the tumor and tumor microenvironment. In HCC, autophagy plays a vital role in tumor immunity, oxidative stress, and the maintenance of hepatic homeostasis and thus participates in HCC initiation and progression and resistance to chemotherapy drugs. Identification of the mechanisms by which autophagy is activated in HCC will help clarify HCC pathogenesis and reveal novel treatments for HCC patients. Numerous investigations have indicated that oncogenic IncRNAs that function as ceRNAs are required for promoting autophagy in HCC. For example, autophagy-related genes 3, 5, 7, and 12 (ATG3, ATG5, ATG7, and ATG12, respectively) are major regulators of the induction of autophagosome formation. The IncRNA PVT1 promotes autophagy in HCC by enhancing ATG3 expression by sponging miR-365. The IncRNA HNF1A-AS1 upregulates the expression of ATG5 in HCC by acting as a sponge of hsa-miR-30b-5p, thus stimulating autophagy. The IncRNA CCAT1 serves as a ceRNA for miR-181a-5p to induce autophagy in HCC by enhancing ATG7 expression. The IncRNA HCG11 promotes autophagy in HCC by enhancing ATG12 expression by sponging miR-26a-5p. In addition, mitogen-activated protein kinase kinase kinase kinase 3 (MAP4K3), an upstream kinase of the MAPK pathway, is a key node in the regulation of autophagy. The IncRNA LINC00665 facilitates autophagy by sponging miR-186-5p to enhance MAP4K3 expression. Collectively, these results suggest that the IncRNA-mediated ceRNA network could provide novel treatments for HCC patients.

**Angiogenesis**

Angiogenesis is responsible for HCC growth, proliferation, invasion, and metastasis. The mechanisms underlying HCC angiogenesis are complex, and exploration of the factors involved in regulating HCC angiogenesis is of great significance for improving antiangiogenic treatments for HCC. Emerging evidence indicates that oncogenic IncRNAs that act as ceRNAs are tightly linked to HCC angiogenesis. For instance, sphingosine kinase 1 (SPHK1), a key metabolic enzyme, is correlated with tumor angiogenesis. A study found that the IncRNA HULC promotes angiogenesis by upregulating SPHK1 in HCC; HULC acts as a ceRNA to increase the expression of transcription factor E2F1 by competitively binding to miR-107 and subsequently results in the activation of the SPHK1 promoter, thus promoting HCC angiogenesis in vivo. In addition, the IncRNA MALAT1 can promote HCC angiogenesis by sponging miR-3064-5p to activate the forkhead box A1 (FOXA1)/CD24/Src pathway or by functioning as a miR-140 sponge to enhance vascular endothelial growth factor A expression. Similarly, LINC00488, another IncRNA, upregulates the expression of talin 1 to facilitate HCC angiogenesis by sponging miR-330-5p. These findings suggest that the IncRNA-mediated ceRNA network may be a promising target for antiangiogenic therapies for HCC.

**Liver cancer stem cells**

LCSCs exhibit high proliferation, self-renewal, high tumorigenicity, chemoresistance, and radioresistance, and their abundance is positively associated with the degree...
of HCC malignancy. Elucidation of the regulatory mechanisms of LCSCs will contribute to our understanding of the pathogenesis of HCC and the identification of novel therapeutic strategies. Existing evidence has shown that oncogenic lncRNAs help sustain cancer stem cell (CSC) traits by acting as ceRNAs for miRNAs to initiate HCC development. For instance, the lncRNA MALAT1 activates the phosphoinositide-3-kinase/protein kinase B (PI3K/Akt) pathway by acting as a miR-124 sponge to enhance HBx-induced CSC properties\(^6\). In addition, catenin beta-1 (CTNNB1)/\(\beta\)-catenin sustains the stemness properties of LCSCs\(^6\). In another recent study, it was found that the lncRNA DANCR was highly expressed in HCC tissues and stem-like HCC cells; DANCR can act as a ceRNA to enhance CTNNB1 expression by sponging miR-214, miR-320a, and miR-199a, thereby enhancing the stemness of HCC cells\(^6\).

Thus, the lncRNA-mediated ceRNA network may serve as a potential therapeutic target for LCSCs.

**Proliferation, migration, EMT, invasion, and metastasis**

The lncRNA-mediated ceRNA regulatory network functions by regulating miRNA target genes: LncRNAs acting as ceRNAs can participate in cell proliferation, apoptosis, migration, EMT, invasion, and metastasis by modulating mRNAs in HCC. Currently, there are many lncRNA-miRNA-miRNA target gene (mRNA) networks reported in HCC. In this review, we provide only a few examples of lncRNA-miRNA-mRNA networks, including those involving oncogenic lncRNAs such as HULC, HOTAIR, CCAT, and ANRIL and tumor suppressive lncRNAs such as GAS5 and MEG3.

**LncRNA HULC-miRNA-mRNA:** HULC has been identified as a specifically highly expressed lncRNA in HCC\(^6\). In a recent study, high HULC expression in HCC was significantly connected to increased lymph node metastasis and advanced TNM stage\(^6\). This finding indicates that HULC can facilitate the proliferation, migration, invasion, and metastasis of HCC cells, leading to the malignant development of HCC. Thus far, it has been reported that HULC may exert its oncogenic function in HCC through diverse molecular mechanisms, of which the HULC-mediated ceRNA network is important. For instance, zinc finger E-box binding homeobox 1 (ZEB1), a key regulator of EMT, contributes to HCC cell invasion and metastasis\(^6\). As a ceRNA of miR-200a-3p, HULC increases the expression of ZEB1, thereby enhancing EMT and promoting HCC growth and metastasis\(^6\). In addition, HULC can enhance the expression of hepatocyte growth factor receptor (MET) by sponging miR-2052, thus promoting HCC cell proliferation, migration, and invasion\(^6\). High mobility group AT-hook 2 (HMGA2), an oncogene, has been shown to be closely associated with cancer progression and metastasis\(^6\). HULC promotes HCC growth and metastasis by enhancing HMGA2 expression by acting as a ceRNA of miR-186\(^6\). Rabla, a central regulatory protein, promotes exosome secretion, and exosomes significantly promote HCC progression\(^6\). A mechanistic investigation revealed that HULC increases Ras oncogene family member expression to induce exosome secretion by sponging miR-372-3p, contributing to HCC growth and metastasis\(^6\).

**LncRNA HOTAIR-miRNA-mRNA:** The lncRNA HOTAIR has been reported to exert an oncogenic role in a variety of malignancies\(^6\). Emerging evidence suggests that HOTAIR functions as a ceRNA and facilitates HCC cell proliferation, migration, invasion, and metastasis. For instance, a study confirmed that HOTAIR promotes HCC cell proliferation and tumorigenicity by competitively binding to miR-218 to activate B-catenin and sustain CSC traits. In another recent study, it was found that HOTAIR enhances FLOT1 expression by sponging miR-214-3p, thereby promoting HCC cell proliferation, migration, and invasion\(^6\). Additionally, HOTAIR promotes HCC cell invasion and metastasis by sponging miR-23b-3p to upregulate ZEB1 expression\(^6\).

**LncRNA CCAT-miRNA-mRNA:** The lncRNA CCAT1 is located on chromosome 8q24.21 and plays vital roles in promoting HCC cell proliferation and metastasis\(^6\). CCAT1 has been shown to upregulate the expression of its downstream gene c-Myc, thereby promoting tumorigenesis\(^6\). Subsequently, many studies have explored the potential mechanism by which CCAT1 upregulates c-Myc to promote tumorigenesis. In HCC, CCAT1 functions as a ceRNA of miRNA let-7, thus counteracting the inhibitory effect of Let-7 on its target genes, HMGA2 and c-Myc, which upregulates the
expression of HMGA2 and c-Myc and ultimately facilitates HCC proliferation and migration\(^9\). In addition, CCAT1 upregulates cyclin-dependent kinase 1 expression by acting as a miR-490-3p sponge, thereby promoting HCC cell proliferation and invasion\(^8\). Furthermore, CCAT1 acts as a sponge of miR-30c-2-3p to upregulate the expression of cyclin E1, leading to HCC cell proliferation\(^1\).

**LncRNA ANRIL-miRNA-mRNA:** The lncRNA ANRIL is located on chromosome 9p21 and plays an oncogenic role in tumorigenesis\(^4\). ANRIL functions as a ceRNA to sponge miRNAs, thereby regulating gene expression in HCC. The high expression of ANRIL in HCC is related to HCC cell proliferation, migration, and invasion; mechanistically, ANRIL exerts its biological action in HCC by sponging miR-384 to upregulate signal transducer and activator of transcription 3 (STAT3) expression\(^9\). ANRIL can also promote HCC cell proliferation, metastasis, and invasion by acting as a ceRNA of miR-122-5p\(^8\). In addition, ANRIL can upregulate the expression of pre-B-cell leukemia homeobox 3 by sponging miR-144 to facilitate HCC cell growth, migration, and invasion\(^9\).

**LncRNA GAS5-miRNA-mRNA:** The lncRNA GAS5 is downregulated in diverse malignancies, including HCC\(^9\). Increasing evidence indicates that the GAS5-mediated ceRNA network may be one of the important mechanisms by which GAS5 exerts its biological functions in HCC. For example, GAS5 restrains HCC cell migration and invasion by sponging miR-21 to upregulate its target, programmed cell death 4 and phosphatase and tensin homolog (PTEN)\(^9\). In addition, GAS5 suppresses HCC invasion by sponging miR-135b to enhance cysteine-rich protein with Kazal motifs expression\(^9\). GAS5 also functions as a miR-1323 sponge to upregulate tumor protein p53-induced nuclear protein 1 expression, thus inhibiting HCC cell proliferation and invasion and promoting apoptosis\(^9\).

**LncRNA MEG3-miRNA-mRNA:** MEG3 is an imprinted gene and a tumor suppressive IncRNA. MEG3 is inversely related to tumorigenesis and plays an inhibitory role in many malignancies\(^9\). Acting as a ceRNA against miRNA is an important mechanism of action of MEG3 in HCC. For example, the overexpression of MEG3 can promote cell apoptosis and inhibit HCC growth by upregulating SRY-related HMG-box transcription factor 11 expression by acting as a miR-9-5p sponge\(^9\). In addition, MEG3 enhances the expression of PTEN to restrain HCC cell proliferation, migration, and invasion by sponging miRNA-10a-5p\(^9\).

**The lncRNA-mediated ceRNA regulatory network functions by modulating signaling pathways:** LncRNAs acting as ceRNAs can also participate in HCC cell proliferation, migration, EMT, invasion, and metastasis by modulating various signaling pathways in HCC, including the Wnt/β-catenin pathway, PI3K/AKT pathway, and nuclear factor kappa-B (NF-kB) pathway.

**Wnt/β-catenin pathway:** Abnormal activation of the Wnt/β-catenin pathway, a key event implicated in HCC carcinogenesis, is believed to be a key target for the clinical diagnosis and treatment of HCC\(^9\). Thus, elucidation of the regulatory mechanisms of the Wnt/β-catenin pathway will provide new insights into a new anticancer therapy for HCC. Extensive evidence to date has indicated that IncRNAs can mediate the Wnt/β-catenin pathway by acting as ceRNAs of miRNAs, thereby modulating HCC cell proliferation and invasion; oncogenic IncRNAs that act as ceRNAs can perform their biological actions by activating the Wnt/β-catenin pathway in HCC. For example, frizzled (FZD) 4, a Wnt receptor, can activate the Wnt/β-catenin pathway in HCC\(^9\), and the lncRNA ASB16-AS1 enhances FZD4 expression to activate the Wnt/β-catenin pathway by acting as a miR-1827 sponge and subsequently facilitates HCC growth and invasion\(^9\). Likewise, another Wnt receptor, FZD7, can also activate the Wnt/β-catenin pathway in HCC\(^9\). The lncRNA DSCR8 activates the Wnt/β-catenin pathway by enhancing FZD7 expression by acting as a miR-485-5p sponge to facilitate HCC cell proliferation and the cell cycle\(^9\). Wingless-type MMTV integration site family 3A (WNT3A) is one of the crucial components of the Wnt/β-catenin pathway related to HCC progression\(^10\), and the lncRNA LINCO00662 activates the Wnt/β-catenin pathway by enhancing WNT3A expression via the competitive sponging of miR-15a, miR-16, and miR-107, thereby promoting HCC growth and metastasis\(^10\). Glycogen synthase kinase 3β (GSK3β) is a pivotal regulator of β-catenin signaling\(^8\), and the lncRNA SNHG5 acts as a miR-26a-5p sponge to enhance GSK3β expression, thereby activating the Wnt/β-catenin pathway to facilitate HCC metastasis and EMT\(^8\). In addition, sex determining region Y-box (SOX) 9 can activate the Wnt/β-catenin pathway in HCC\(^9\), and the lncRNA SOX9-AS1 facilitates HCC growth and
metastasis by increasing SOX9 expression to activate the Wnt/β-catenin pathway by acting as a miR-5590-3p sponge\textsuperscript{114}. In HCC, interleukin (IL)-6 is associated with the activation of Janus kinase 2 (JAK2)/STAT3 signaling\textsuperscript{115}; cyclin-dependent kinase (CDK) 8 and low-density lipoprotein receptor-related protein 6 (LRP6) are associated with the activation of Wnt/β-catenin signaling\textsuperscript{116,117}, and the lncRNA DLGAP1-AS1 increases the expression of IL-6 and CDK8/LRP6 by functioning as a sponge of miR-26a-5p and miR-26b-5p, thereby activating JAK2/STAT3 and Wnt/β-catenin signaling, to facilitate EMT and the progression of HCC, respectively\textsuperscript{118}. Instead, tumor suppressive lncRNAs that act as ceRNAs function by inactivating Wnt/β-catenin signaling in HCC. For example, in HCC, nuclear receptor corepressor 2 is associated with inhibition of the activation of Wnt/β-catenin signaling\textsuperscript{119}. MIR22HG, a tumor suppressive lncRNA, increases NCOA2 expression by sponging miR-10a-5p, thereby inactivating Wnt/β-catenin signaling to inhibit HCC cell growth, migration, and invasion\textsuperscript{120}. The abovementioned findings suggest that different lncRNA-mediated ceRNA networks can exert their biological functions in HCC by mediating the Wnt/β-catenin pathway; these networks may become effective therapeutic targets for treating HCC patients.

**PI3K/AKT pathway:** PI3K/AKT, a highly activated pathway in HCC, is implicated in HCC carcinogenesis and chemoresistance\textsuperscript{121-124}. At present, emerging evidence indicates that multiple lncRNA-mediated ceRNA networks can exert their biological functions by modulating the PI3K/AKT pathway, among which oncogenic lncRNAs that act as ceRNAs exert their biological function by activating the PI3K/AKT pathway in HCC. For instance, the lncRNA PTTG3P facilitates the proliferation, migration, and invasion and inhibits the apoptosis of HCC cells by increasing the expression of cyclin D1/poly ADP-ribose polymerase 2 and activating the PI3K/Akt pathway by acting as a ceRNA of miR-383\textsuperscript{125}. Similarly, the lncRNA DLEU1 activates the PI3K/Akt pathway by increasing insulin-like growth factor 1 receptor-1 expression by sponging miR-133a, thereby facilitating HCC cell proliferation, migration and invasion\textsuperscript{126}. By contrast, tumor suppressive lncRNAs that act as ceRNAs can exert their biological function by inactivating the PI3K/Akt pathway in HCC. For instance, TCL6, a tumor suppressive lncRNA, upregulates Pten expression by sponging miR-106a-5p to suppress the PI3K/AKT pathway, thereby inhibiting HCC cell proliferation, migration, and invasion\textsuperscript{127}. Intriguingly, several oncogenic lncRNAs that act as ceRNAs have been reported to exert their biological functions by activating the PI3K/AKT/mammalian rapamycin (mTOR) or PI3K/AKT/FoxO3a pathway in HCC. For example, the lncRNA CDKN2B-AS1, an oncogenic lncRNA, enhances nucleosome assembly protein 1 like 1 expression by acting as a ceRNA of let-7a-5p, thus activating the PI3K/AKT/mTOR pathway to promote HCC cell growth and metastasis\textsuperscript{128}. In addition, the lncRNA GAS6-AS2 activates the PI3K/AKT/FoxO3a pathway by upregulating OTU domain-containing ubiquitin aldehyde-binding protein 1 expression by sponging miR-493-5p, which promotes HCC cell proliferation, migration, and invasion\textsuperscript{129}. In short, the lncRNA-miRNA-PI3K/AKT, PI3K/AKT/mTOR or PI3K-AKT-FoxO3a regulatory network is expected to be a potential therapeutic target for the treatment of HCC patients.

**NF-κB pathway:** Numerous studies have shown that abnormal activation of the NF-κB pathway is related to HCC growth, EMT, and invasion\textsuperscript{120-122}. Existing evidence suggests that lncRNAs can act as miRNA sponges and exert their biological function by modulating the NF-κB pathway in HCC. For example, in the NF-κB pathway, mixed-lineage kinase (MLK) 3 contributes to cancer migration, invasion, and metastasis\textsuperscript{123,124}, and the lncRNA SNHG12 enhances MLK3 expression by competitively sponging miR-199a/b-5p, thereby activating the NF-κB pathway to promote HCC proliferation and tumorigenicity\textsuperscript{125}. By contrast, a tumor suppressive lncRNA that acts as a ceRNA can exert its biological function by inactivating the NF-κB pathway in HCC. For example, CYLD, a tumor suppressor, can negatively regulate the NF-κB pathway in HCC\textsuperscript{126}, and the lncRNA CASC2, a tumor suppressive lncRNA, suppresses the NF-κB pathway by enhancing CYLD expression by sponging miR-362-5p, thereby inhibiting HCC cell migration and invasion\textsuperscript{127,128}. These findings indicate that the lncRNA-miRNA-NF-κB pathway network may serve as a therapeutic target for patients with HCC.

**Chemoresistance and radioresistance**

Although current chemotherapy and radiotherapy regimens can prolong the survival of HCC patients, tumor recurrence and metastasis due to chemoresistance and...
radioresistance lead to unsatisfactory long-term efficacy. The underlying mechanisms of therapeutic resistance in HCC are still unclear, and the exploration of such mechanisms will help improve the current treatment of HCC. Emerging evidence suggests that lncRNAs play a critical role in mediating chemoresistance and radioresistance by acting as ceRNAs of miRNAs in HCC.

Currently, the lncRNA-mediated ceRNA network has been proven to mediate HCC resistance to chemotherapy drugs, including sorafenib, oxaliplatin, cisplatin, and 5-fluorouracil (5-FU). Exploration of the resistance mechanisms to chemotherapy drugs in the treatment of HCC will provide new insights into overcoming chemoresistance.

Sorafenib has been approved for treating advanced HCC; however, the emergence of sorafenib resistance has affected the efficacy of HCC treatment. Existing studies have shown that the lncRNA-mediated ceRNA network is responsible for HCC resistance to sorafenib. Specifically, oncogenic lncRNAs that act as ceRNAs can enhance HCC resistance to sorafenib. For example, activation of the c-Met-Akt pathway can promote sorafenib resistance in HCC cells\[^{[13]}\], and the lncRNA NEAT1 activates the c-Met-Akt pathway by sponging miR-335 to enhance sorafenib resistance in HCC cells\[^{[13]}\]. In addition, recent studies have suggested that the abnormal activation or expression of forkhead box M1 (FoxM1) contributes to chemoresistance in various cancer cells\[^{[13]}\]. In HCC cells, FoxM1 knockout sensitizes drug-resistant HCC cells to sorafenib\[^{[13]}\], and the lncRNA LINC-ROR increases sorafenib resistance in HCC cells by elevating FOXM1 expression by sponging miR-876-5p\[^{[14]}\]. Phosphoinositide-3-kinase regulatory subunit 3 (PIK3R3), a regulatory subunit of PI3K, activates the PI3K/AKT pathway to enhance the resistance of HCC cells to sorafenib-induced apoptosis\[^{[15]}\], and the lncRNA LINC00160 acts as a miR-132 sponge to promote sorafenib resistance by increasing PIK3R3 expression in HCC cells\[^{[16]}\].

Transmembrane protein 9 (TMEM9) plays a vital role in HCC cell growth\[^{[17]}\], and the lncRNA FOXD2-AS1 upregulates TMEM9 expression by sponging miR-150-5p to facilitate the resistance of HCC cells to sorafenib\[^{[18]}\]. The tetraspanin protein CD151 has been shown to attenuate drug-induced apoptosis in cancer cell lines\[^{[19]}\], and the lncRNA SNHG3 enhances CD151 expression by acting as a ceRNA for miR-128 to promote HCC resistance to sorafenib\[^{[20]}\]. Additionally, the lncRNA SNHG16 is upregulated in sorafenib-resistant HCC cells, and SNHG16 increases sorafenib resistance partly by competitively sponging miR-140-5p\[^{[21]}\].

Oxaliplatin has been approved for the treatment of patients with locally advanced and metastatic HCC who are not eligible for surgical resection or local treatment; however, oxaliplatin resistance affects the efficacy of HCC treatment. The lncRNA-mediated ceRNA network has been confirmed to modulate oxaliplatin resistance in HCC. In particular, oncogenic lncRNAs that act as ceRNAs can enhance HCC resistance to oxaliplatin. For instance, HULC can upregulate the expression of the ubiquitin-specific peptidase 22 (USP22) protein by suppressing miR-6825-5p, miR-6845-5p, and miR-6886-3p at the epigenetic or transcriptional level in HCC cells; USP22 enhances the HULC-induced deubiquitination of Sirt1 and stabilizes it, and Sirt1 stability induces the autophagy of HCC cells, thus increasing the resistance of HCC cells to oxaliplatin\[^{[22]}\]. Multidrug resistance-associated protein 1 (ABCC1) is indicative of chemoresistance\[^{[23]}\], and the lncRNA NR2F1-AS1 elevates ABCC1 expression by sponging miR-363 to enhance oxaliplatin resistance in HCC cells\[^{[24]}\]. Similarly, the lncRNA KCNQ1OT1 increases oxaliplatin resistance in HCC cells by sponging miR-7-5p to elevate ABCC1 expression\[^{[25]}\].

The antitumor efficacy of cisplatin in the treatment of advanced HCC patients is unsatisfactory due to drug resistance. The lncRNA-mediated ceRNA network has been demonstrated to modulate cisplatin resistance in HCC, among which oncogenic lncRNAs that act as ceRNAs can enhance HCC resistance to cisplatin. For example, nuclear factor erythroid-2-related factor 2 (Nrf2) is upregulated in HepG2/cisplatin cells and mediates the chemoresistance of HCC cells to cisplatin\[^{[26]}\]. The lncRNA NRAL increases Nrf2 expression by sponging miR-340-5p, thereby facilitating cisplatin resistance in HCC cells\[^{[27]}\]. Melanoma-associated antigen A3 (MAGEA3) enhances chemoresistance to cisplatin in HepG2 cells, and the lncRNA LINC01234 enhances MAGEA3 expression by sponging miR-31-5p to promote cisplatin resistance in HCC\[^{[28]}\]. The lncRNA SNHG16 enhances cisplatin resistance in HCC cells by sponging let-7b-5p\[^{[29]}\]. Conversely, tumor suppressive lncRNAs that act as ceRNAs can reduce HCC resistance to cisplatin. For example, the overexpression of CASC2, a tumor suppressor lncRNA, strengthens cisplatin sensitivity in HCC cells by sponging miR-222\[^{[30]}\]. In addition, the overexpression of GAS5, another tumor suppressor lncRNA, enhances the sensitivity of HCC cells to cisplatin by sponging miR-222\[^{[30]}\].

The inhibitory efficacy of 5-FU on HCC cells is limited by chemical resistance. Emerging evidence indicates that the lncRNA-mediated ceRNA network is correlated
with 5-FU resistance in HCC cells, among which oncogenic lncRNAs that act as ceRNAs can enhance HCC resistance to 5-FU. For example, the IncRNA CRNDE acts as a ceRNA of miR-33a in HCC to enhance HMGA2 expression, thereby promoting chemoresistance to 5-FU in HCC cells[126]. HIF-2α is related to the resistance of HCC cells to doxorubicin and sorafenib[135], and the IncRNA MALAT1 acts as a ceRNA to increase HIF-2α expression by competitively sponging miR-216b, leading to the enhanced chemoresistance of HCC cells to 5-FU[127]. In contrast, tumor suppressive lncRNAs that act as ceRNAs can reduce HCC resistance to 5-FU. For example, Kelch-like ECH-associated protein 1 (Keap1) inactivation enhances the resistance of HCC cells to chemotherapy drugs such as sorafenib[154,169], and the overexpression of KRAL, a tumor suppressive IncRNA, enhances Keap1 inactivation by acting as a ceRNA for miR-141 to reverse the resistance to 5-FU in HCC cell lines[160].

Currently, an oncogenic lncRNA-mediated ceRNA network has been demonstrated to enhance HCC resistance to radiation therapy. For instance, AZD1775, an inhibitor of WEE1, has been reported to sensitize HCC cells to radiation[104], suggesting that WEE1 can enhance radioresistance in HCC. The IncRNA NEAT1_2 upregulates WEE1 expression by acting as a ceRNA for miR-101-3p to reduce the radiosensitivity of HCC[119]. A RING-type ubiquitin ligase E3 (RAD18), an E3 ubiquitin-linked enzyme, can induce radiation resistance in glioma cells[165]. The IncRNA LINC-ROR competes with sponge miR-145 to increase RAD18 expression, thereby enhancing the radiation resistance of HCC cells[120]. Forkhead box protein P1 (FOXP1), a transcription factor, attenuates radioresistance in cervical cancer[121]. The IncRNA LINC00473 promotes radioresistance in HCC by increasing FOXP1 expression by sponging miR-345-5p[122]. These findings suggest that the IncRNA-mediated ceRNA network may provide new clues for overcoming radioresistance in HCC.

PROBLEMS AND PERSPECTIVES

The IncRNA-mediated ceRNA regulatory network provides a new mode of posttranscriptional regulation and plays a critical role in the initiation and progression of HCC. Nevertheless, investigations into the detailed mechanism of the ceRNA network and its relationship with HCC are still in the preliminary stage. Although there are increasing reports about IncRNAs as ceRNAs in HCC, several fundamental problems facing these studies need to be addressed. First, information on the roles of lncRNAs that act as ceRNAs in current studies is derived from overexpression and/or knockout experiments, and only when the abundance of IncRNAs is remarkably high can lncRNAs act as ceRNAs. As a result, the abundance of artificially controlled lncRNAs often far exceeds the abundance range of any endogenous IncRNA. Therefore, it is urgent to verify whether the IncRNA-mediated ceRNA network has the same effects under normal cellular conditions. Second, most of the current research on ceRNAs is still in the prediction stage of bioinformatics, and most studies lack biological validation; the regulatory relationships in the ceRNA network need to be effectively verified. Third, methodologically, there are few predictive tools available; most miRNA-mRNA predictions focus only on the binding of a miRNA with its target in the 3′-UTR. However, this is not always the case; miRNAs can also target the 5′-untranslated region and coding sequences of mRNAs[136-138]. Thus, provided that the prediction of a ceRNA is not limited to the 3′-UTR of its mRNA, the range of predicted ceRNAs should be improved. Fourth, one miRNA generally interacts with one target mRNA. However, some miRNAs may modulate many target mRNAs, and vice versa[139-141]. Thus, it is necessary to model the effect of ceRNAs in real scenarios. Fifth, the ceRNA hypothesis maintains that a miRNA is stably expressed; in fact, intracellular miRNA expression is dynamic, which inevitably influences the effectiveness of ceRNAs. Sixth, although ceRNA prediction methods are constantly updated, the current prediction algorithms cannot fully encompass several factors affecting ceRNA susceptibility (quantity and characteristics of MREs, miRNA/mRNA abundance, and subcellular location of RNAs)[142-144]. Therefore, the prediction methods and experimental methods still need to be further updated and improved. Seventh, the initiation and progression of HCC are a complex event, and it is unclear whether other mechanisms interact with IncRNAs acting as ceRNAs in HCC cells. Addressing the above problems will enable a better understanding of the IncRNA-mediated ceRNA network that can be used to more effectively diagnose and treat HCC.

Given the critical roles and the complex interactions among IncRNA-mediated ceRNA regulatory networks in HCC, future investigations with validation in large sample sizes and the exploration of in-depth molecular mechanisms are needed to
probe the HCC-specific lncRNA-mediated ceRNA axis, which should identify new diagnostic and prognostic markers of HCC and provide promising targets for the treatment of patients with HCC.

REFERENCES


Lu B, Ferrandino AF, Flavell RA. Gadd45beta is important for perpetuating cognate and inflammatory signals in T cells. Nat Immunol 2004; 5: 38-44 [PMID: 14691461 DOI: 10.1038/ni0120]


Shan Y, Li P. Long Intergenic Non-Protein Coding RNA 665 Regulates Viability, Apoptosis, and Autophagy via the Mr-186-5p/MAP4K3 Axis in Hepatocellular Carcinoma. Yonsei Med J 2019; 60: 842-
activating P14 and P16 signaling.


LncRNA-mediated ceRNA network in HCC

Niu ZS et al.

10.1016/j.ijepd.2015.05.016


Lin XY, Zheng F. miR-340 reverses cisplatin resistance of hepatocellular carcinoma cell lines by targeting hepatocellular carcinoma through miR-7-5p/ABCC1 axis. [PMID: 29602203]


Chen S, Xia X. Long noncoding RNA NEAT1 suppresses sorafenib sensitivity of hepatocellular carcinoma cells via regulating miR-335-3p. [PMID: 30937906]

Westhoff GL, Chen Y, Teng NHH. Targeting FOXM1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer. [PMID: 28692634]


WJG  170
166
165
164
163
162
161
160
158
156
154
153
151
150
149
148
147
Broughton JP
[PMID: 10.1002/jcb.29477]

